{"preliminary_commentary":{"by_channel":{"x_thread":4,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"HARMONi-GI3","nct_id":"NCT07228832","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=harmoni-gi3-nct07228832. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"HARMONi-GI3","arms":[{"description":"Subjects will receive Ivonescimab Plus mFOLFOX6 via intravenous infusion (IV) Q2W, up to 8 cycles. Afterward, Ivonescimab plus Leucovorin and 5-FU will be used for maintenance treatment (administered on Day 1 of each cycle, Q2W) up to 2 years.","label":"Arm A: Ivonescimab in combination with mFOLFOX6","type":"EXPERIMENTAL"},{"description":"Subjects will receive bevacizumab Plus mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) via intravenous infusion (IV) Q2W, up to 8 cycles in treatment periods per the randomization schedule. Afterward, bevacizumab Plus 5-FU and Leucovorin will be used for maintenance treatment (administered on Day 1 of each cycle, Q2W) up to 2 years.","label":"Arm B: Bevacizumab in combination with mFOLFOX6","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-11-30","type":"ESTIMATED"},"conditions":["Metastatic Colorectal Cancer (CRC)"],"enrollment":{"count":600,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Drug: Ivonescimab Injection","otherNames":["Oxaliplatin","Leucovorin","5-Fluorouracil"],"type":"DRUG"},{"name":"Drug: Bevacizumab Injection","otherNames":["Oxaliplatin","Leucovorin","5-Fluorouracil"],"type":"DRUG"}],"last_update":"2026-10-06","lead_sponsor":"Summit Therapeutics","official_title":"A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination With FOLFOX Versus Bevacizumab in Combination With FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-05-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"PFS by IRRC based on RECIST v1.1","timeFrame":"Up to approximately 2.5 years"}],"references":[],"start_date":{"date":"2025-11-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer","url":"https://clinicaltrials.gov/study/NCT07228832"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/harmoni-gi3-nct07228832"}